365 related articles for article (PubMed ID: 7911078)
1. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
Gold JE; Osband ME
Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
3. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
4. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
5. Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.
Gold JE; Masters TR; Osband ME
J Surg Res; 1995 Aug; 59(2):279-86. PubMed ID: 7543632
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.
Gold JE; Ross SD; Krellenstein DJ; LaRosa F; Malamud SC; Osband ME
Eur J Cancer; 1995; 31A(5):698-708. PubMed ID: 7640041
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Bloom ND; Shafir MK; Klein MJ; Kenan S; Osband ME
J Surg Oncol; 1995 Apr; 58(4):212-21. PubMed ID: 7723363
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
9. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
Mazumder A; Rosenberg SA
J Exp Med; 1984 Feb; 159(2):495-507. PubMed ID: 6141211
[TBL] [Abstract][Full Text] [Related]
10. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Bleiweiss IJ; Goldfarb AB; Bauer JJ; Gelernt IM; Schwartz ME; Reiner MA; Miller CM; Weiss MF; Brower ST
J Surg Oncol; 1994 Apr; 55(4):222-8. PubMed ID: 8159004
[TBL] [Abstract][Full Text] [Related]
11. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
12. A novel approach to generate host antitumor T cells: adoptive immunotherapy by T cells maturing in xenogeneic thymus.
Zhao Y; Sun Y; Niu Z; Li Q; Peng J; Wang J; Langnas AN
J Immunother; 2007 Jan; 30(1):83-8. PubMed ID: 17198086
[TBL] [Abstract][Full Text] [Related]
13. Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.
Wang LX; Kjaergaard J; Cohen PA; Shu S; Plautz GE
J Immunol; 2004 Mar; 172(6):3462-8. PubMed ID: 15004146
[TBL] [Abstract][Full Text] [Related]
14. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
15. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Babbit B; Fine EM; Weber HN; Unger PD; Leventhal I; Zippe CD; Osband ME
Br J Urol; 1995 Jul; 76(1):115-22. PubMed ID: 7648042
[TBL] [Abstract][Full Text] [Related]
17. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
[TBL] [Abstract][Full Text] [Related]
18. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.
Hardy B; Yampolski I; Kovjazin R; Galli M; Novogrodsky A
Cancer Res; 1994 Nov; 54(22):5793-6. PubMed ID: 7954401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
